VEGF and its soluble receptor VEGFR-2 in hypertensive disorders during pregnancy: The Indian scenario

Journal of Human Hypertension

Volumn 26, Issue 3, 2012, Pages 196-204

  Rath, G ^a   Tripathi, R ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

enzyme linked immunosorbent assay; hypertensive disorders; VEGF, soluble vascular endothelial growth factor receptor 2

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC VALUE; ECLAMPSIA; FEMALE; GESTATIONAL AGE; HUMAN; HYPOXIA; INDIA; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PATHOGENESIS; PREECLAMPSIA; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY;

ADULT; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; ECLAMPSIA; FEMALE; GESTATIONAL AGE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; INDIA; PRE-ECLAMPSIA; PREGNANCY; SENSITIVITY AND SPECIFICITY; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 84857052300     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.17     Document Type: Article

References (47)

1. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 53.
2. National high blood pressure education program work-ing group on high blood pressure in pregnancy. Report of the National high blood pressure education program working group on high blood pressure in pregnancy. Am J Obst Gyne 2000; 183: s1-s22.
3. Roberts JM, Lain KY. Recent insight into the pathogen-esis of pre-eclampsia. Placenta 2002; 23: 359-372.
4. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dys-function. Microcirculation 2002; 9(3): 147-160. (Pubitemid 135685559)
5. Redman CW, Sargent IL. Latest advances in under-standing pre-eclampsia. Science 2005; 8: 592-1594.
6. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D et al. A naturally occurring soluble form of vascular endothelial growth factor receptor-2 detected in mouse and human plasma. Mol Cancer Res 2004; 2: 315-326. (Pubitemid 39025294)
7. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676. (Pubitemid 36749215)
8. Agostini H, Boden K, Unsold A, Martin G, Hansen L, Fiedler U et al. A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse. Curr Eye Res 2005; 30: 249-257. (Pubitemid 40806646)
9. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML. Failure of blood-island forma-tion and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-66.
10. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439. (Pubitemid 26102719)
11. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L et al. L, Smith LE suppression of retinal neovascularization in vivo by inhibition of VEGF using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 457-461.
12. Rodesch F, Simon P, Donner C, Jauniaux E. Oxygen measurements in endometrial and trophoblastic tis-sues during early pregnancy. Obstet Gynecol 1992; 80: 283-285.
13. Ferrara N, Gerber H. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001; 106: 148-156. (Pubitemid 34124153)
14. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J1999; 13: 9-22. (Pubitemid 29038270)
15. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716. (Pubitemid 36278589)
16. Baker PN, Krasnow J, Roberts JM, Yeo KT. Elevated serum levels of vascular endothelial growth factor in patients with pre-eclampsia. Obstet Gynecol 1995; 86: 815-821.
17. Sharkey AM, Cooper JC, Balmforth JR, Mclaren J, Clark DE, Charnock-Jones DS et al. Maternal plasma levels of vascular endothelial growth factor in normotensive pregnancies and pregnancies complicated by pre-eclampsia. Eur J Clin Invest 1996; 26: 1182-1185.
18. Lyall F, Greer IA, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunor-eactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynecol 1997; 104: 223-228. (Pubitemid 27065149)
19. Chaiworapongsa T, Romero R, Gotsch F, Espinoza J, Nien JK, Goncalves L et al. Low maternal concentra-tions of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestation age. JMatern Fetal Neonatal Med 2008; 21: 41-52.
20. Tripathi R, Rath G, Jain A, Salhan S. Soluble and membranous vascular endothelial growth factor recep-tor-1 in pregnancies complicated by pre-eclampsia. Ann Anat 2008; 190: 477-489.
21. Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee KY, Goncalves LF et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of pre-eclampsia. Young Investigator Award. Am J Obstet Gynecol 2004; 190: 1541-1547.
22. Oh MJ, Shin JC, Popek EJ. Vascular endothelial growth factor expression in patients complicated pre-eclamp-sia. Korean J Obstet Gynecol 2001; 44: 1877-1882.
23. Lee ES, Oh MJ, Jung JW, Lim JE, Seol HJ, Lee KJ et al. The Levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by pre-eclampsia. J Korean Med Sci 2007; 22(1): 94-98.
24. Levine RJ, Maynard SE, Qian C, Lim KH, Lucinda J, Yu KF et al. Circulating angiogenic factors and the risk of pre-eclampsia. N Engl J Med 2004; 350: 672-683. (Pubitemid 38364626)
25. Hunter A, Aitkenhead M, Caldwell C, Mc Cracken G, Wilson D, Mc Clure N. Serum levels of vascular endothelial growth factor in preeclamptic and normo-tensive pregnancy. Hypertension 2000; 36(6): 965-969.
26. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardi-ovasc Res 2005; 65: 550-563. (Pubitemid 40138976)
27. Faderl S, Do KA, Johnson MM, Keating M, O'brien S, Jilani I et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia (ALL). Blood 2005; 106: 4303-4307. (Pubitemid 41775940)
28. Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y Circulating angiogenic factors in pre-eclampsia, gestational proteinuria and pre-eclampsia superimposed on chronic glomerulone-phritis. Am JObstet Gynecol 2006; 194: 551-556. (Pubitemid 43183715)
29. Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond) 2007; 112(1): 51-57. (Pubitemid 46120085)
30. Kendall RL, Thomas KA. Inhibition of VEGF activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-10709. (Pubitemid 23347111)
31. Ebos JM, Lee CR, Bogdanovic E, Alami J, Slyke PV, Francia G et al. Vascular endothelial growth factor- mediated decrease in plasma soluble vascular en-dothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 2008; 68(2): 521-529. (Pubitemid 351380080)
32. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci 2006; 11: 818-829. (Pubitemid 43262905)
33. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothe-lial growth factor receptor genes. Flt-1, but not Flk-1/ KDR, is upregulated by hypoxia. J Biol Chem 1997; 272: 23659-23667. (Pubitemid 27410939)
34. Kim SY, Park SY, Kim JW, Kim YM, Yang JH, Kim MY Circulating endothelial progenitor cells, plasma VEGF, and VEGFR-1 and VEGFR-2 levels in pre-eclampsia. Am J Obstet Gynecol 2005; 193: S74.
35. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999-1007. (Pubitemid 41262334)
36. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syn-dromes (CHAMPS): population-based retrospective cohort study. Lancet 2005; 366: 1797-1803. (Pubitemid 41642644)
37. Roberts DM, Kearney JB, Johnson JH, Rosenberg MP, Kumar R, Bautch VL. The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am JPathol 2004; 164: 1531-1535. (Pubitemid 38529755)
38. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. Excess placental soluble fms-like tyrosine kinase 1(s Flt-1) may contribute to endothelial dysfunc-tion, hypertension and proteinuria in pre-eclampsia. J Clin Invest 2003; 111: 649-658. (Pubitemid 36278583)
39. Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from Flt tyrosine kinase, a receptor for vascular endothelial growth factor (VEGF). Oncogene 1995; 10: 135-147.
40. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745. (Pubitemid 28155313)
41. Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of con-version of the maternal spiral arteries for uteroplacen-tal blood flow during human pregnancy. Placenta 2009; 30(6): 473-482.
42. Escudero C, Puebla C, Westermeier F, Sobrevia L. Potential cell signalling mechanisms involved in differ-ential placental angiogenesis in mild and severe pre-eclampsia. Curr Vasc Pharmacol 2009; 7(4): 475-485.
43. Roy H, Bhardwaj S, Ylä-Herttuala S. Biology of vascular endothelial growth factors. FEBS Letters 2006; 580(12): 2879-2887. (Pubitemid 43729175)
44. Munaut C, Lorquet S, Pequeux C, Blacher S, Berndt S, Frankenne F et al. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 2008; 23(6): 1407-1415. (Pubitemid 351770590)
45. Wilting J, Birkenhager R, Eichmann A, Kurz H, Martinybaron G, Marme D et al. VEGF(121) induces proliferation of vascular endothelial cells and expres-sion of flk-1 without affecting lymphatic vessels of the chorioallantoic membrane. Dev Biol 1996; 176: 76-85.
46. Kumazaki K, Nakayama M, Suehara N, Wada Y. Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathological condi-tions. Hum Pathol 2002; 33: 1069-1077. (Pubitemid 35416703)
47. Salahuddin S, Young L, Vadnais M, Benjamin P, Sachs S, Karumanchi A et al. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Amer J Obst Gynec 2007; 197: 28.e1-28.e6.